Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 146

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 146
---
of the management of our business is vested in our board of directors. Our board of directors may exercise all powers and may take all
actions that are not specifically granted to our shareholders or to executive management. Our Chief Executive Officer (referred to as
a “general manager” under the Companies Law) is responsible for our day-to-day management. Our Chief Executive Officer is
appointed by, and serves at the discretion of, our board of directors, subject to the employment agreement that we have entered into with
him. All other executive officers are appointed by the Chief Executive Officer and are subject to the terms of any applicable employment
agreements that we may enter into with them.

Under our articles of association and the Companies Law, our board
of directors must consist of not less than three and no more than seven directors. Currently our board of directors consists of six directors.

Our directors are elected annually, by a simple majority vote of
holders of our voting shares participating and voting at the annual meeting of our shareholders, for a one-year term, from the annual
general meeting of our shareholders at which they are elected until the next annual general meeting and until their respective successors
are elected and qualified or until their earlier removal by our shareholders at a general meeting, or upon the occurrence of certain events,
in accordance with the Companies Law and our articles of association. The duration of service of each of our current directors can be
found in their respective biographies in Item 6. A. above.

In addition, under our articles of association, our board of directors
may appoint directors to fill vacancies or as new directors for a term of office that lasts until the next annual meeting of our shareholders.
In the event of a vacancy resulting in the board consisting of less than the minimum number of directors required by our articles of association,
our board of directors may only act in order to convene a general meeting of our shareholders for the purpose of electing such additional
number of directors.

Pursuant to the terms of a put option agreement we entered into
with Monsanto (now Bayer) in October 2013, Monsanto has the right to nominate a non-voting observer to our board of directors so long
as Monsanto holds at least 5% of our voting rights. In addition, pursuant to a share purchase agreement we entered into with Bayer in
December 2010 and as amended in June 2013, Bayer also has the right to appoint one observer to our board of directors so long as Bayer
holds at least 3%